捐献来源的CD19修饰的嵌合抗原受体T细胞治疗

icartab

Donor-derived CD19 chimeric antigen receptor T cells.

Abstract

PURPOSE OF REVIEW:

As immunotherapy matures into possible front-line therapy, new approaches are necessary to expand the capacity to treat more patients. Although most technologies for chimeric antigen receptor (CAR) therapies require autologous T cells, 'off the shelf' sources are highly desired.

RECENT FINDINGS:

Sources of T cells for modification with CARs include cord blood and either related or unrelated allogeneic donors. Strategies to manipulate these sources focus on reducing the risk of alloreactivity, while maintaining the potential for high function and long persistence associated with successful CAR T-cell therapies.

SUMMARY:

Recent research implies that manipulating nonautologous T-cell sources can result in well tolerated and effective products, but work remains to determine if these approaches will reach the efficacy of autologous products.

捐献来源的CD19修饰的嵌合抗原受体T细胞治疗

摘要

回顾的目的

随着免疫治疗的成熟，可能会进入一线治疗，新的治疗方式是必须的，以扩大治疗更多数量的患者。虽然大多数的嵌合抗原受体修饰的技术需要使用自体细胞，但是“非自己”的细胞资源还是非常需要的。

最新进展：

改造CARs的T细胞来源包括了脐带血和其他相关或非相关的异基因供体。使用这些资源的主要策略集中在降低同种异体反应风险，同时成功保持CAR-T细胞治疗的高效性和持久性。

概要

最近的研究表明：操纵异体的T细胞能够有较好的耐受性和有效性，但是还是需要确定这些异体细胞治疗方法能否达到治疗的有效性。

出自爱康得生物技术